Intravitreal dexamethasone implant in treatment of recurrent toxoplasmosis posterior uveitis

Poster Details

First Author: I.Pastukh UKRAINE

Co Author(s):    N. Goncharova   O. Shkil   U. Diomin                       

Abstract Details


To present and analyze results of intravitreal dexamethasone implant (Ozurdex®) in treatment of recurrent toxoplasmosis posterior uveitis.


Ophthalmology Department, Kharkov Medical Academy of Postgraduate Education, Ukraine


Three adult patients (3 eyes) with recurrent toxoplasmosis posterior uveitis were assigned to receive dexamethasone 0.7 mg sustained–release intravitreal implant. Visometry, tonometry, biomicroscopy, ultrasound of eye, optical coherence retinal tomography (OCT), fundus photographs were evaluated. Laboratory tests included investigations of blood and urine. X-Ray examinations were performed. We observed tolerability of the implant and the incidence and severity of ocular or systemic adverse events. Term of observation is 2 years.


After 1 and 2 weeks of follow-up our patients gained visual acute on 50-70%; OCT showed a mean decrease of central retinal thickness (CRT) on 60-70%. During 2-nd week intraocular pressure (IOP) increased in one patient (1 eye) and brimonidine eye drops were admitted for 1 month. Vitreous precipitates disappeared after 3 weeks in all eyes. No recurrent attacks of posterior uveitis we observed during two years. No patients experienced a severe adverse events that were attributed to Ozurdex®.


Ozurdex® is generally well-tolerated, may improve visual acute and vitreous condition, decrease CRT in patients with recurrent posterior uveitis. IOP continued to normalize for the patients to 1 month. We received positive clinical effect of Ozurdex® in treatment of our patients with recurrent posterior toxoplasmosis uveiti

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy